---
title: "United Imaging Healthcare (688271): Won the procurement project of the Guangxi Zhuang Autonomous Region Cancer Prevention and Control Research Institute, with a winning amount of 7.445 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289159894.md"
description: "United Imaging Healthcare announced that it won the bid for the procurement project of the Guangxi Zhuang Autonomous Region Cancer Prevention and Treatment Research Institute, with a bid amount of 7.445 million yuan. The company mainly focuses on medical imaging diagnostic equipment and radiation therapy equipment, with a revenue of 13.8 billion yuan and a net profit of 1.869 billion yuan in 2025; in the first quarter of 2026, the revenue was 2.908 billion yuan and the net profit was 399 million yuan"
datetime: "2026-06-09T08:40:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289159894.md)
  - [en](https://longbridge.com/en/news/289159894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289159894.md)
generator: "portal-rs"
---

# United Imaging Healthcare (688271): Won the procurement project of the Guangxi Zhuang Autonomous Region Cancer Prevention and Control Research Institute, with a winning amount of 7.445 million yuan

According to Tongbi Finance, data from Qichacha shows that based on the "Announcement of the Bidding Results for the Procurement Project of Two Devices including CT Simulation Positioning Machine by Yunzhilong Consulting Group Co., Ltd. (Heavy) GXZC2026-G1-001186-YZLZ," Shanghai United Imaging Healthcare Co., Ltd. announced on June 9, 2026, that it won the bid for the procurement project by the Guangxi Zhuang Autonomous Region Tumor Prevention and Treatment Research Institute, with a winning amount of 7.445 million yuan.

Related listed company: United Imaging Healthcare (688271.SH)

*Tongbi Finance Tip:*

*United Imaging Healthcare (688271.SH) reported an operating income of 13.8 billion yuan in 2025, with an operating income growth rate of 33.98%. The net profit attributable to the parent company was 1.869 billion yuan, with a net profit growth rate of 48.14%, and a return on equity of 9.00%.*

*In the first quarter of 2026, the company's operating income was 2.908 billion yuan, with an operating income growth rate of 17.34%. The net profit attributable to the parent company was 399 million yuan, with a net profit growth rate of 7.78%.*

*Currently, the company belongs to the healthcare industry, with the main product type being diagnostic and therapeutic equipment. The 2025 report shows that the main composition of revenue comes from the sales of medical imaging diagnostic equipment and radiation therapy equipment: 82.53%; maintenance revenue: 12.38%; other businesses: 4.69%; software revenue: 0.39%.*

### Related Stocks

- [688271.CN](https://longbridge.com/en/quote/688271.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Capella University Announces Appointment of Oncology Leader Dr. Saro Sarkisian to Board of Trustees | STRA Stock News](https://longbridge.com/en/news/296481766.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)
- [BioArctic and Mesenkia enter oncology research collaboration](https://longbridge.com/en/news/296333958.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**